BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPS cells

TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies

By

Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-StemTM technology for cell therapy mass-production.

Bordeaux, France, February 5, 2020 – TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, today announces the appointment of 2 senior executives and 2 independent board members. Pascale Berthet, formerly Business Development Manager at FUJIFILM Cellular Dynamics was appointed Chief Business Development Officer, and Michaël Lanero Fidalgo, former Head of EMEA Biodevelopment Center at Merck KGaA, was recruited as Chief Operating Officer. In addition, 2 independent board members joined TreeFrog Therapeutics’ corporate governance: Julia Berretta, formerly VP of Business Development at Cellectis, and Frederic Desdouits, former Bionest Partner and Pierre Fabre North America director. [Read more…]

Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating iPS Cells

By

Lineage Cell and AgeX get issued U.S. Patent that Precedes the first scientific publication of Shinya Yamanaka.

CARLSBAD, Calif., Dec 10, 2019 — Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells” covering what is commonly designated “induced Pluripotent Stem (iPS) cells.” The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body.

The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012. [Read more…]

Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering

By

National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board

REDWOOD CITY, Calif., Oct. 22, 2019 — Synthego, the leading genome engineering company, announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. [Read more…]

What Are Induced Pluripotent Stem Cells? | iPS Cell Definition

By

Induced pluripotent stem cells (iPS cells) are differentiated cells that are reprogrammed back into an embryonic-like state. Derived from skin or blood cells, iPS cells are not controversial, because they are made from adult cells. As pluripotent stem cells, they can give rise to nearly all of the tissues that form the human body. [Read more…]

Century Therapeutics Launches With $250 Million for Allogeneic iPSC Platform

By

  • Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies

  • Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments

July 01, 2019, LEVERKUSEN, Germany & PHILADELPHIA & TOKYO–Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, emerged from stealth mode today with USD 250 million in financing commitments from Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. [Read more…]

BioInformant's World-Class Clients